Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Pelthos Therapeutics Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 3.83M shares outstanding
USPelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older.
It also provides NITRICIL, a proprietary nitric oxide-based technology platform.
The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Leadership
Employees
4
Country
US
Sector
Healthcare
Website
pelthos.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Greenleaf Peter | Director | Sale | 797 | $16.9K | Oct 2, 2026 |
 Friedberg Ezra M | Director | Sale | 558 | $11.6K | Oct 2, 2026 |
 Pauls Matthew | Director | Sale | 786 | $16.5K | Oct 2, 2026 |
| Pauls Matthew | Director | Sale | 692 | $18.0K | Jul 2, 2026 |
| Pauls Matthew | Director | Sale | 94 | $2.6K | Jul 2, 2026 |
| Friedberg Ezra M | Director | Sale | 24 | $655.81 | Jul 2, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Ligand Pharmaceuticals Incorporated · may incl. warrants· filed Jul 2025 | 4.9M | 49.9% as filed | 13D |
 LIGAND PHARMACEUTICALS INC 10% Owner | 1.5M | 39.2% | FORM 4 |
Alexandra Wood (Canada) Inc. · may incl. warrants· filed Jan 2025 | 574.2K | 9.5% as filed | 13G |
Motif Pharmaceuticals Ltd. · may incl. warrants· filed Mar 2024 | 483.4K | 8.4% as filed | 13G |
Boswell Prayer Ltd · may incl. warrants· filed Mar 2024 | 471.6K | 8.2% as filed | 13G |
Aperture Healthcare Ventures Ltd. · may incl. warrants· filed Mar 2024 | 444.1K | 7.7% as filed | 13G |
Benuvia Operations, LLC · may incl. warrants· stale · filed Mar 2024 | 384.2K | 10.0% | 13G |
3i, LP · joint filing· may incl. warrants· filed May 2026 | 337.0K | 8.8% | 13G |
AIGH Capital Management LLC | 329.1K | 8.6% | 13F |
Murchinson Ltd. | 304.3K | 7.9% | 13F |
Insiders
- Greenleaf PeterDirector
- Friedberg Ezra MDirector
- Pauls MatthewDirector
- Davis Todd CDirector
- Francis Knuettel IICFO, Treas & Secty
- Malamut RichardDirector
- Einhorn Andrew J.Director
- LIGAND PHARMACEUTICALS INC10% Owner
- Plesha Scott M.CEO and President
- Rangarao SaiChief Commercial Officer
based on 3.83M shares outstanding
US30d Avg
50.97K
60d Avg
46.67K
90d Avg
59.81K